These findings deepen our knowledge of the biologic actions of GH axis augmentation among PLWH with NAFLD, demonstrating suppression of key circulating angiogenic, fibrogenic, and pro-inflammatory mediators, with evidence linking tesamorelin-mediated changes in these pathways to improvements in key histologic and transcriptomic indices. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.